As the Government begins to ease lockdown restrictions, the question now remains, will the market continue on its V-shape recovery or will there be more volatility on the horizon?
In this webinar recording, Kien and Mat will share insights on how you could use our renowned quantitative methodology to help you weather the economic downturn, regardless of the current market volatility. We understand that this is a once in a generation opportunity to invest in oversold financially healthy quality stocks.
Using the same Financial Health methodology that is available through Stock Doctor, our Lincoln Wholesale Australian Growth Fund was ranked #1 of 43 funds for performance over 3-years to 30/04/2020 in the Equity Australia Mid/Small Growth category, achieving an Overall Morningstar Rating of 4 stars*.
In this webinar Kien and Mat will discuss:
- Using our academically proven Financial Health Model to identify financially unhealthy stocks and those at risk of failure like Virgin Australia.
- Identifying investment opportunities with our Star Stock recommendations.
- Proactively managing your portfolio with Stock Doctor’s essential tool set and one of our four proven strategies, based on your tolerance and sensitivity to share market volatility.
- Our Managed Fund options including the pending launch of our U.S. Growth Funds.
Special EOFY Offer: Hear about our new EOFY Offer. Don’t miss out!
Head of Research
Kien leads the Stock Doctor research team and has extensive experience in the investment field, specifically in quantitative research techniques. He previously worked in the role of Portfolio Manager and Senior Quantitative Analyst at Patersons Securities for over 10 years, and prior to that, at Russell Investment providing portfolio construction and risk management strategies to large scale institutional clients including Telstra Super and UniSuper. With a background in actuarial finance, Kien is responsible for the current Stock Doctor research process, including Lincoln’s acclaimed Financial Health methodology. He is a key contributor in evolving our research processes and is a mentor to the Stock Doctor research team.
Stock Doctor Expert
Mathew having been with Lincoln over 5 years champions the Stock Doctor New Sales team to share and integrate the Lincoln methodology and capabilities of the Stock Doctor platform, empowering retail, SMSF and professional investors to meet their current and evolving market objectives.